HomeCompareAMGXF vs FCPT

AMGXF vs FCPT: Dividend Comparison 2026

AMGXF yields 555.25% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGXF wins by $139385.03M in total portfolio value
10 years
AMGXF
AMGXF
● Live price
555.25%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$139385.08M
Annual income
$102,921,608,523.78
Full AMGXF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — AMGXF vs FCPT

📍 AMGXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGXFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGXF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGXF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGXF
Annual income on $10K today (after 15% tax)
$47,196.00/yr
After 10yr DRIP, annual income (after tax)
$87,483,367,245.21/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, AMGXF beats the other by $87,483,362,336.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGXF + FCPT for your $10,000?

AMGXF: 50%FCPT: 50%
100% FCPT50/50100% AMGXF
Portfolio after 10yr
$69692.57M
Annual income
$51,460,807,149.53/yr
Blended yield
73.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

AMGXF
No analyst data
Altman Z
-9.8
Piotroski
4/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGXF buys
0
FCPT buys
0
No recent congressional trades found for AMGXF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGXFFCPT
Forward yield555.25%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$139385.08M$49.1K
Annual income after 10y$102,921,608,523.78$5,775.28
Total dividends collected$136290.63M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: AMGXF vs FCPT ($10,000, DRIP)

YearAMGXF PortfolioAMGXF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$66,225$55,524.71$11,401$700.92+$54.8KAMGXF
2$414,515$343,654.92$13,064$864.84+$401.5KAMGXF
3$2,453,824$2,010,292.98$15,051$1,072.48+$2.44MAMGXF
4$13,747,478$11,121,885.96$17,442$1,337.22+$13.73MAMGXF
5$72,943,478$58,233,676.89$20,340$1,677.08+$72.92MAMGXF
6$366,820,716$288,771,193.86$23,880$2,116.57+$366.80MAMGXF
7$1,749,678,241$1,357,180,074.99$28,241$2,689.36+$1749.65MAMGXF
8$7,922,192,769$6,050,037,051.08$33,660$3,442.07+$7922.16MAMGXF
9$34,078,014,001$25,601,267,737.85$40,456$4,439.95+$34077.97MAMGXF
10$139,385,083,504$102,921,608,523.78$49,063$5,775.28+$139385.03MAMGXF

AMGXF vs FCPT: Complete Analysis 2026

AMGXFStock

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

Full AMGXF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this AMGXF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGXF vs SCHDAMGXF vs JEPIAMGXF vs OAMGXF vs KOAMGXF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.